The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.
 
Jeremy S. Abramson
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Celgene; EMD Serono; Genentech; Gilead Sciences; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Merck; Novartis; Seagen; Verastem
Research Funding - AI Therapeutics (Inst); Celgene (Inst); genentech (Inst); Juno Therapeutics (Inst); Seagen (Inst)
 
Maria Lia Palomba
Stock and Other Ownership Interests - Seres Therapeutics (I)
Honoraria - Amgen (I); Celgene; Evelo Therapeutics (I); Flagship Biosciences (I); Jazz Pharmaceuticals (I); Merck; Merck (I); Novartis (I); Pharmacyclics; Seres Therapeutics (I); Therakos (I)
Consulting or Advisory Role - Amgen (I); Celgene; Evelo Therapeutics (I); Flagship Biosciences (I); Jazz Pharmaceuticals (I); Merck; Merck (I); Novartis (I); Seres Therapeutics (I); Therakos (I)
Research Funding - Seres Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (I); Juno intellectual property rights (Inst)
 
Jon E. Arnason
Consulting or Advisory Role - Juno Therapeutics
Research Funding - Juno Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Bayer; Celgene; Genentech; Genzyme; Gilead Sciences; Janssen Oncology; Juno Therapeutics; Kite, a Gilead company; Novartis; Pharmacyclics; Portola Pharmaceuticals; Seagen; Spectrum Pharmaceuticals; TG Therapeutics; Verastem
Research Funding - Celgene (Inst); Celgene (Inst); Celgene (Inst); Curis (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Juno Therapeutics (Inst); miRagen (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
 
Scott R. Solomon
No Relationships to Disclose
 
Thalia Farazi
No Relationships to Disclose
 
Jacob Garcia
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Amgen; Celgene
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Travel, Accommodations, Expenses - Celgene
 
Benhuai Xie
Employment - Juno Therapeutics; Juno Therapeutics (I)
Stock and Other Ownership Interests - Juno Therapeutics; Juno Therapeutics (I)
 
Kathryn J. Newhall
Employment - Celgene
Stock and Other Ownership Interests - Amgen; Celgene
Travel, Accommodations, Expenses - Celgene
 
Christine Dehner
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
Tanya Siddiqi
Consulting or Advisory Role - AstraZeneca; BeiGene; Juno Therapeutics; Pharmacyclics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics